Access
To read this story in full you will need to login or make a payment (see right).
Article
Nature Medicine 11, 50 - 55 (2004)
Published online: 26 December 2004 | doi:10.1038/nm1164
Inhibition of respiratory viruses by nasally administered siRNA
Vira Bitko1, Alla Musiyenko1, Olena Shulyayeva1 & Sailen Barik1
Abstract
Respiratory syncytial virus (RSV) and parainfluenza virus (PIV) are two respiratory pathogens of paramount medical significance that exert high mortality. At present, there is no reliable vaccine or antiviral drug against either virus. Using an RNA interference (RNAi) approach, we show that individual as well as joint infection by RSV and PIV can be specifically prevented and inhibited by short interfering RNAs (siRNAs), instilled intranasally in the mouse, with or without transfection reagents. The degree of protection matched the antiviral activity of the siRNA in cell culture, allowing an avenue for quick screening of an efficacious siRNA. When targeting both viruses in a joint infection, excess of one siRNA moderated the inhibitory effect of the other, suggesting competition for the RNAi machinery. Our results suggest that, if properly designed, low dosages of inhaled siRNA might offer a fast, potent and easily administrable antiviral regimen against respiratory viral diseases in humans.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
RNAi tackles a sexually transmitted diseaseNature Biotechnology News and Views (01 Jan 2006)
RESEARCH
A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3Nature Medicine Article (01 Jan 2000)
Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 geneNature Medicine Article (01 Jan 2005)
See all 37 matches for Research